Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Cash from Operations (2016 - 2025)

Adma Biologics' Cash from Operations history spans 13 years, with the latest figure at 35639000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 29.03% year-over-year to 35639000.0; the TTM value through Dec 2025 reached 50396000.0, down 57.53%, while the annual FY2025 figure was 50396000.0, 57.53% down from the prior year.
  • Cash from Operations reached 35639000.0 in Q4 2025 per ADMA's latest filing, up from 13293000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 50216000.0 in Q4 2024 to a low of 33465250.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 299550.0, with a median of 6719029.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: skyrocketed 853.36% in 2024, then tumbled 787.06% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 33465250.0 in 2021, then soared by 77.95% to 7379058.0 in 2022, then soared by 338.47% to 17597000.0 in 2023, then surged by 185.37% to 50216000.0 in 2024, then fell by 29.03% to 35639000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Cash from Operations are 35639000.0 (Q4 2025), 13293000.0 (Q3 2025), and 21139000.0 (Q2 2025).